Cardioxyl Pharma reports $28M equity round with lead drug against heart failure FierceBiotech The potential payoff is huge as heart failure rates rise and continue to be a leading cause of hospitalizations among the older crowd, with massive costs to the healthcare system. Earlier this week Novartis ($NVS) detailed some mixed Phase III results ... |
